Intellia Therapeutics Ownership | Who Owns Intellia Therapeutics?


OverviewForecastRevenueFinancialsChartTranscripts

Intellia Therapeutics Ownership Summary


Intellia Therapeutics is owned by 73.36% institutional investors, 4.51% insiders, and 22.13% retail investors. Ark investment management is the largest institutional shareholder, holding 13.39% of NTLA shares. ARK Disruptive Innovation Full Composite is the top mutual fund, with 7.88% of its assets in Intellia Therapeutics shares.

NTLA Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockIntellia Therapeutics73.36%4.51%22.13%
SectorHealthcare Stocks 232.80%10.63%-143.43%
IndustryBiotech Stocks 379.48%10.37%-289.85%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Ark investment management14.51M13.39%$186.01M
Vanguard group13.01M11.81%$116.96M
Blackrock funding, inc. /de12.16M11.22%$155.84M
Blackrock9.60M10.05%$214.79M
State street6.92M6.39%$88.75M
D. e. shaw5.73M5.29%$73.44M
Two sigma investments, lp4.71M4.34%$60.33M
Regeneron pharmaceuticals3.70M3.42%$47.47M
Baker bros. advisors lp2.75M2.65%$47.44M
Geode capital management2.85M2.63%$36.56M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Regeneron pharmaceuticals3.70M99.14%$47.47M
Birchview capital, lp445.40K3.25%$5.71M
Contrarius investment management1.92M2.68%$42.87M
Ark investment management14.51M1.45%$186.01M
Contrarius group1.91M1.39%$24.51M
Orchard capital management82.03K1.10%$1.05M
Iq eq fund management (ireland)724.29K0.71%$9.29M
Canal insurance230.00K0.63%$2.95M
Himension capital (singapore) pte.429.54K0.42%$5.51M
Opaleye management245.00K0.41%$3.14M

Top Buyers

HolderShares% AssetsChange
Two sigma investments, lp4.71M0.05%2.01M
Vanguard group13.01M0.00%1.97M
Blackrock funding, inc. /de12.16M0.00%1.88M
Ubs group2.69M0.01%1.83M
Arrowstreet capital, limited partnership1.40M0.01%1.40M

Top Sellers

HolderShares% AssetsChange
Deep track capital, lp---4.95M
Capital investors---3.78M
Renaissance---1.67M
Rokos capital management llp---1.14M
Trexquant investment lp270.12K0.05%-857.22K

New Positions

HolderShares% AssetsChangeValue
Arrowstreet capital, limited partnership1.40M0.01%1.40M$17.91M
Vanguard fiduciary trust748.10K0.00%748.10K$9.59M
Farallon capital management607.20K0.04%607.20K$10.49M
Steadfast capital management lp365.40K0.11%365.40K$6.31M
Casdin capital355.00K0.34%355.00K$4.55M

Sold Out

HolderChange
Global financial private client-1.00
Activest wealth management-1.00
Dinuzzo private wealth-1.00
Jfs wealth advisors-2.00
Richard w. paul & associates-2.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 2025221-28.25%80,835,304-22.43%730.82%102-32.45%72-10.00%
Sep 30, 20252891.05%103,222,25512.82%991.28%143-2.72%76-8.43%
Jun 30, 2025290-7.05%98,735,343-2.49%950.99%146-0.68%85-10.53%
Mar 31, 20256-98.05%3,804,135-96.17%30.04%3-98.41%1-98.55%
Dec 31, 2024286-2.39%92,252,291-1.01%911.07%17817.11%61-27.38%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
ARK Disruptive Innovation Full Composite9.31M7.88%333.26K
ARK Innovation ETF9.90M7.30%1.96M
American Funds SMALLCAP World A3.78M3.65%3.78M
Vanguard Total Stock Mkt Idx Inv3.67M3.11%27.28K
State Street® SPDR® S&P® Biotech ETF4.18M3.08%-41.38K
Vanguard US Total Market Shares ETF3.17M3.06%299.88K
ARK Genomic Revolution ETF3.50M2.58%487.84K
ARK Genomic Revolution2.87M2.43%-132.03K
Vanguard Small Cap Index2.72M2.31%92.49K
iShares Russell 2000 ETF2.62M1.88%22.14K

Recent Insider Transactions


DateNameRoleActivityValue
Mar 02, 2026BASTA JAMES EVP, General CounselSell$16.69K
Mar 02, 2026Clark Eliana EVP, Chief Technical OfficerSell$8.36K
Jan 05, 2026LEONARD JOHN M President and CEOSell$314.48K
Jan 05, 2026Schultes Birgit C EVP, Chief Scientific OfficerSell$78.36K
Jan 05, 2026BASTA JAMES EVP, General CounselSell$95.76K

Insider Transactions Trends


DateBuySell
2026 Q119
2025 Q4-5
2025 Q314
2025 Q2-2
2025 Q1-11

NTLA Ownership FAQ


Who Owns Intellia Therapeutics?

Intellia Therapeutics shareholders are primarily institutional investors at 73.36%, followed by 4.51% insiders and 22.13% retail investors. The average institutional ownership in Intellia Therapeutics's industry, Biotech Stocks , is 379.48%, which Intellia Therapeutics falls below.

Who owns the most shares of Intellia Therapeutics?

Intellia Therapeutics’s largest shareholders are Ark investment management (14.51M shares, 13.39%), Vanguard group (13.01M shares, 11.81%), and Blackrock funding, inc. /de (12.16M shares, 11.22%). Together, they hold 36.41% of Intellia Therapeutics’s total shares outstanding.

Does Blackrock own Intellia Therapeutics?

Yes, BlackRock owns 10.05% of Intellia Therapeutics, totaling 9.6M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 214.79M$. In the last quarter, BlackRock increased its holdings by 488.34K shares, a 5.36% change.

Who is Intellia Therapeutics’s biggest shareholder by percentage of total assets invested?

Regeneron pharmaceuticals is Intellia Therapeutics’s biggest shareholder by percentage of total assets invested, with 99.14% of its assets in 3.7M Intellia Therapeutics shares, valued at 47.47M$.

Who is the top mutual fund holder of Intellia Therapeutics shares?

ARK Disruptive Innovation Full Composite is the top mutual fund holder of Intellia Therapeutics shares, with 7.88% of its total shares outstanding invested in 9.31M Intellia Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools